Isomorphic Labs, Alphabet Inc.’s AI-driven drug discovery company, has raised US$600 million in its first round of external funding.

The investment was led by Thrive Capital, with participation from Alphabet and its venture capital arm, GV.

The company’s valuation following this round has not been disclosed.

Founded in 2021, Isomorphic Labs was spun out from DeepMind, Alphabet’s AI division acquired in 2014. It is led by Demis Hassabis, who also oversees Google’s AI initiatives.

In 2024, the company announced partnerships with pharmaceutical giants Novartis AG and Eli Lilly & Co.

This funding round follows another instance of an Alphabet-owned entity raising external capital.

Recent Alphabet developments